These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21820815)

  • 41. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
    Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
    Lheureux S; N'Diaye M; Blanc-Fournier C; Dugué AE; Clarisse B; Dutoit S; Giffard F; Abeilard E; Briand M; Labiche A; Grellard JM; Crouet H; Martin S; Joly F; Poulain L
    Int J Cancer; 2015 Mar; 136(5):E340-50. PubMed ID: 25066666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
    Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
    Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer.
    Özdemir E; Çiçek T; Kaya MO
    Urol J; 2012; 9(3):568-73. PubMed ID: 22903479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
    Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
    Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
    Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
    Wong KK; Lu KH; Malpica A; Bodurka DC; Shvartsman HS; Schmandt RE; Thornton AD; Deavers MT; Silva EG; Gershenson DM
    Int J Gynecol Pathol; 2007 Oct; 26(4):404-9. PubMed ID: 17885490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
    Ali-Fehmi R; Morris RT; Bandyopadhyay S; Che M; Schimp V; Malone JM; Munkarah AR
    Am J Obstet Gynecol; 2005 Mar; 192(3):819-25. PubMed ID: 15746677
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
    Tan Y; Sinniah R; Bay BH; Singh G
    J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Updates on histologic grading and pathogenesis of ovarian serous carcinomas].
    Shen Y; Yang F; Liu JS
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):507-10. PubMed ID: 22169636
    [No Abstract]   [Full Text] [Related]  

  • 51. [Expression of folate receptor alpha in ovarian epithelial tumors].
    Shen DH; Xie JL; Zhang YL; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

  • 55. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue.
    Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
    Tumour Biol; 2014 Jan; 35(1):277-86. PubMed ID: 23918300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lectin binding to serous ovarian tumours.
    Söderström KO
    J Clin Pathol; 1988 Mar; 41(3):308-13. PubMed ID: 2452177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study.
    Garg G; Yilmaz A; Kumar P; Turkoglu O; Mutch DG; Powell MA; Rosen B; Bahado-Singh RO; Graham SF
    Metabolomics; 2018 Nov; 14(12):154. PubMed ID: 30830441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. YKL-40 tissue expression and plasma levels in patients with ovarian cancer.
    Høgdall EV; Ringsholt M; Høgdall CK; Christensen IJ; Johansen JS; Kjaer SK; Blaakaer J; Ostenfeld-Møller L; Price PA; Christensen LH
    BMC Cancer; 2009 Jan; 9():8. PubMed ID: 19134206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proteome profiling of low grade serous ovarian cancer.
    Zadeh Fakhar HB; Zali H; Rezaie-Tavirani M; Darkhaneh RF; Babaabasi B
    J Ovarian Res; 2019 Jul; 12(1):64. PubMed ID: 31315664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of chitinase-like proteins in cancer.
    Kzhyshkowska J; Yin S; Liu T; Riabov V; Mitrofanova I
    Biol Chem; 2016 Mar; 397(3):231-47. PubMed ID: 26733160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.